The docetaxel (T), carboplatin (C) and trastuzumab (H) regimen has been used in the (neo-) adjuvant treatment of HER2+ early stage breast cancer (ESBC).
Lapatinib (L) a small molecule HER2 antagonist produces clinical responses following H failure.
